Clinical Trial Results:
Randomized study on the hemodynamic effect of the association of simvastatin with non-cardioselective beta-blockers in patients with liver cirrhosis and clinically significant portal hypertension.
Summary
|
|
EudraCT number |
2010-022516-39 |
Trial protocol |
ES |
Global end of trial date |
04 Mar 2016
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
09 Jul 2022
|
First version publication date |
09 Jul 2022
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
SIMBETA
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau – IIB Sant Pau
|
||
Sponsor organisation address |
c/ Sant Quintí, 77-79 , BARCELONA, Spain, 08041
|
||
Public contact |
UICEC Sant Pau, Institut de Recerca Hospital de la Santa Creu i Sant Pau, 0034 935537636, uicec@santpau.cat
|
||
Scientific contact |
UICEC Sant Pau, Institut de Recerca Hospital de la Santa Creu i Sant Pau, 0034 935537636, uicec@santpau.cat
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
17 May 2015
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
15 May 2015
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
04 Mar 2016
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The main objective will be to assess whether, in patients with compensated cirrhosis, portal hypertension greater than 10mmHg and esophageal varices at risk, the association of a selective hepatic vasodilator such as simvastatin together with non-cardioselective beta-blockers may have any long-term hemodynamic effect.
|
||
Protection of trial subjects |
The study will be conducted in strict accordance with international ethical recommendations for research and clinical trials in humans. Likewise, the standards contained in the Declaration of Helsinki will be guaranteed and will be developed in accordance with the protocol and with the standard work procedures (SOPs) that ensure compliance with the standards of Good Clinical Practice (PCB). The investigator should explain to the patient (when possible) or his authorized legal representative, the nature of the study, its purposes, procedures, estimated duration, the potential risks and benefits related to the participation in the study, as well as any inconvenience that this may cause. can suppose. Each of the participants should be warned that their participation in the study is voluntary and that they can leave the study at any time, without this affecting their subsequent treatment or their relationship with the professionals who treat them. For this, an information / consent sheet has been designed for the patient or the authorized legal representative, which is attached.
|
||
Background therapy |
Carvedilol (Cv), a non-selective β-blockers (NSBBs) with capacity to ameliorate hepatic vascular resistance (HVR), is more effective than traditional-NSBBs to reduce the hepatic venous pressure gradient (HVPG). Statins may also decrease portal hypertension by reducing the HVR by improving endothelial function. Whether the addition of statins may improve the hemodynamic effects of carvedilol in cirrhosis with clinically significant portal hypertension (CSPH) has not been clarified. This study aimed to evaluate whether the addition of simvastatin (Sv) can improve the hemodynamic effects of carvedilol in cirrhosis with CSPH and without previous HVPG response to NSBBs. | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
20 Oct 2011
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Spain: 82
|
||
Worldwide total number of subjects |
82
|
||
EEA total number of subjects |
82
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
82
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||
Recruitment
|
|||||||||||||
Recruitment details |
Patients of both sexes, with liver cirrhosis, older than 18 years and younger than 80 years who meet all the inclusion criteria and do not meet any exclusion criteria. | ||||||||||||
Pre-assignment
|
|||||||||||||
Screening details |
- Liver cirrhosis diagnosed by previous biopsy or by clinical, analytical and ultrasound criteria. -PPG >10 mmHg. -Presence of large esophageal varices or small esophageal varices with red dots, esophageal varices of any size and Pugh C, and/or fundic gastric varices of any size, in a recent gastroscopy (< 1 month) | ||||||||||||
Period 1
|
|||||||||||||
Period 1 title |
BASELINE (overall period)
|
||||||||||||
Is this the baseline period? |
Yes | ||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||
Blinding used |
Double blind | ||||||||||||
Roles blinded |
Subject, Investigator | ||||||||||||
Arms
|
|||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||
Arm title
|
CARVEDILOL + PLACEBO | ||||||||||||
Arm description |
- | ||||||||||||
Arm type |
Active comparator | ||||||||||||
Investigational medicinal product name |
CARVEDILOL
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||||
Routes of administration |
Oral use
|
||||||||||||
Dosage and administration details |
6.25 mg/ 24h
|
||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||||
Routes of administration |
Oral use
|
||||||||||||
Dosage and administration details |
XXXXX
|
||||||||||||
Arm title
|
CARVEDILOL + SIMVASTATINA | ||||||||||||
Arm description |
- | ||||||||||||
Arm type |
Experimental | ||||||||||||
Investigational medicinal product name |
CARVEDILOL
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||||
Routes of administration |
Oral use
|
||||||||||||
Dosage and administration details |
6.25 mg/ 24
|
||||||||||||
Investigational medicinal product name |
SIMVASTATINA
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||||
Routes of administration |
Oral use
|
||||||||||||
Dosage and administration details |
20 mg/ 24h
|
||||||||||||
|
|
|
|||
End points reporting groups
|
|||
Reporting group title |
CARVEDILOL + PLACEBO
|
||
Reporting group description |
- | ||
Reporting group title |
CARVEDILOL + SIMVASTATINA
|
||
Reporting group description |
- |
|
||||||||||
End point title |
hepatic venous pressure gradient | |||||||||
End point description |
||||||||||
End point type |
Primary
|
|||||||||
End point timeframe |
OVERALL PERIOD
|
|||||||||
|
||||||||||
Statistical analysis title |
Descriptive statistical analysis | |||||||||
Comparison groups |
CARVEDILOL + PLACEBO v CARVEDILOL + SIMVASTATINA
|
|||||||||
Number of subjects included in analysis |
82
|
|||||||||
Analysis specification |
Post-hoc
|
|||||||||
Analysis type |
non-inferiority | |||||||||
P-value |
< 0.05 | |||||||||
Method |
Chi-squared | |||||||||
Confidence interval |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Overall period
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
16
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
CARVEDILOL + PLACEBO
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
CARVEDILOL + SIMVASTATINA
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |